Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse

T Ohashi; S Iizuka; Y Shimada; Y Eto; H Ida; S Hachimura; H Kobayashi

doi:10.1016/j.ymgme.2011.01.009

Oral administration of recombinant human acid α-glucosidase reduces specific antibody formation against enzyme in mouse

Mol Genet Metab. 2011 May;103(1):98-100. doi: 10.1016/j.ymgme.2011.01.009. Epub 2011 Jan 27.

Authors

T Ohashi¹, S Iizuka, Y Shimada, Y Eto, H Ida, S Hachimura, H Kobayashi

Affiliation

¹ Department of Gene Therapy, Institute of DNA Medicine, The Jikei University School of Medicine, Tokyo, Japan.

PMID: 21320791
DOI: 10.1016/j.ymgme.2011.01.009

Abstract

Animal and human studies of enzyme replacement therapy for Pompe disease have indicated that antibodies generated against the infused recombinant human acid α-glucosidase (rhGAA) can negatively impact therapeutic outcome. In this study, we show that oral administration of rhGAA into mice can reduce the titer of anti-rhGAA antibody following immunization with rhGAA. Oral administration of rhGAA is safe and antigen specific, it offers advantages over other immunosuppressive drugs.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Animals
Antibodies / blood*
Antibodies / immunology*
Antibody Formation
Disease Models, Animal
Enzyme Replacement Therapy*
Glycogen Storage Disease Type II / immunology*
Glycogen Storage Disease Type II / therapy*
Humans
Immunoglobulin E / blood
Immunoglobulin G / blood
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Recombinant Proteins / administration & dosage
alpha-Glucosidases / immunology*

Substances

Antibodies
Immunoglobulin G
Recombinant Proteins
Immunoglobulin E
GAA protein, human
alpha-Glucosidases